scholarly journals Estimating outflow masses and velocities in merger simulations: Impact of r -process heating and neutrino cooling

2021 ◽  
Vol 104 (12) ◽  
Author(s):  
Francois Foucart ◽  
Philipp Mösta ◽  
Teresita Ramirez ◽  
Alex James Wright ◽  
Siva Darbha ◽  
...  
Keyword(s):  
2021 ◽  
Vol 922 (2) ◽  
pp. 185
Author(s):  
Wataru Ishizaki ◽  
Kenta Kiuchi ◽  
Kunihito Ioka ◽  
Shinya Wanajo

Abstract The gravitational wave event GW170817 with a macronova/kilonova shows that a merger of two neutron stars ejects matter with radioactivity including r-process nucleosynthesis. A part of the ejecta inevitably falls back to the central object, possibly powering long-lasting activities of a short gamma-ray burst (sGRB), such as extended and plateau emissions. We investigate fallback accretion with r-process heating by performing one-dimensional hydrodynamic simulations and developing a semi-analytical model. We show that the usual fallback rate dM/dt ∝ t −5/3 is halted by the heating because pressure gradients accelerate ejecta beyond an escape velocity. The suppression is steeper than Chevalier’s power-law model through Bondi accretion within a turn-around radius. The characteristic halting timescale is ∼104–108 s for the GW170817-like r-process heating, which is longer than the typical timescale of the long-lasting emission of sGRBs. The halting timescale is sensitive to the uncertainty of the r-process. Future observations of fallback halting could constrain the r-process heating on the scale of a year.


2019 ◽  
Vol 485 (3) ◽  
pp. 4404-4412 ◽  
Author(s):  
D Desai ◽  
B D Metzger ◽  
F Foucart

ABSTRACT Mergers of compact binaries containing two neutron stars (NS–NS), or a neutron star and a stellar mass black hole (NS–BH), are likely progenitors of short-duration gamma-ray bursts (SGRBs). A fraction ${\gtrsim } 20{{\ \rm per\ cent}}$ of SGRBs is followed by temporally extended (≳minute-long), variable X-ray emission, attributed to ongoing activity of the central engine. One source of late-time engine activity is fall-back accretion of bound tidal ejecta; however, observed extended emission light curves do not track the naively anticipated, uninterrupted t−5/3 power-law decay, instead showing a lull or gap in emission typically lasting tens of seconds after the burst. Here, we re-examine the impact of heating due to rapid neutron capture (r-process) nucleosynthesis on the rate of the fall-back accretion, using ejecta properties extracted from numerical relativity simulations of NS–BH mergers. Heating by the r-process has its greatest impact on marginally bound matter, hence its relevance to late-time fall-back. Depending on the electron fraction of the ejecta and the mass of the remnant black hole, r-process heating can imprint a range of fall-back behaviour, ranging from temporal gaps of up to tens of seconds to complete late-time cut-off in the accretion rate. This behaviour is robust to realistic variations in the nuclear heating experienced by different parts of the ejecta. Central black holes with masses ${\lesssim } 3\, \mathrm{M}_{\odot }$ typically experience absolute cut-offs in the fall-back rate, while more massive ${\gtrsim } 6\!-\!8\, \mathrm{M}_{\odot }$ black holes instead show temporal gaps. We thus propose that SGRBs showing extended X-ray emission arise from NS–BH, rather than NS–NS, mergers. Our model implies an NS–BH merger detection rate by LIGO that, in steady state, is comparable to or greater than that of NS–NS mergers.


1988 ◽  
Vol 132 ◽  
pp. 501-506
Author(s):  
C. Sneden ◽  
C. A. Pilachowski ◽  
K. K. Gilroy ◽  
J. J. Cowan

Current observational results for the abundances of the very heavy elements (Z>30) in Population II halo stars are reviewed. New high resolution, low noise spectra of many of these extremely metal-poor stars reveal general consistency in their overall abundance patterns. Below Galactic metallicities of [Fe/H] Ã −2, all of the very heavy elements were manufactured almost exclusively in r-process synthesis events. However, there is considerable star-to-star scatter in the overall level of very heavy element abundances, indicating the influence of local supernovas on element production in the very early, unmixed Galactic halo. The s-process appears to contribute substantially to stellar abundances only in stars more metal-rich than [Fe/H] Ã −2.


1976 ◽  
Vol 32 ◽  
pp. 169-182
Author(s):  
B. Kuchowicz

SummaryIsotopic shifts in the lines of the heavy elements in Ap stars, and the characteristic abundance pattern of these elements point to the fact that we are observing mainly the products of rapid neutron capture. The peculiar A stars may be treated as the show windows for the products of a recent r-process in their neighbourhood. This process can be located either in Supernovae exploding in a binary system in which the present Ap stars were secondaries, or in Supernovae exploding in young clusters. Secondary processes, e.g. spontaneous fission or nuclear reactions with highly abundant fission products, may occur further with the r-processed material in the surface of the Ap stars. The role of these stars to the theory of nucleosynthesis and to nuclear physics is emphasized.


2021 ◽  
Vol 103 (2) ◽  
Author(s):  
J.-F. Lemaître ◽  
S. Goriely ◽  
A. Bauswein ◽  
H.-T. Janka

Science ◽  
2021 ◽  
Vol 371 (6532) ◽  
pp. 901.18-903
Author(s):  
Keith T. Smith
Keyword(s):  

2020 ◽  
Vol 36 (S1) ◽  
pp. 37-37
Author(s):  
Americo Cicchetti ◽  
Rossella Di Bidino ◽  
Entela Xoxi ◽  
Irene Luccarini ◽  
Alessia Brigido

IntroductionDifferent value frameworks (VFs) have been proposed in order to translate available evidence on risk-benefit profiles of new treatments into Pricing & Reimbursement (P&R) decisions. However limited evidence is available on the impact of their implementation. It's relevant to distinguish among VFs proposed by scientific societies and providers, which usually are applicable to all treatments, and VFs elaborated by regulatory agencies and health technology assessment (HTA), which focused on specific therapeutic areas. Such heterogeneity in VFs has significant implications in terms of value dimension considered and criteria adopted to define or support a price decision.MethodsA literature research was conducted to identify already proposed or adopted VF for onco-hematology treatments. Both scientific and grey literature were investigated. Then, an ad hoc data collection was conducted for multiple myeloma; breast, prostate and urothelial cancer; and Non Small Cell Lung Cancer (NSCLC) therapies. Pharmaceutical products authorized by European Medicines Agency from January 2014 till December 2019 were identified. Primary sources of data were European Public Assessment Reports and P&R decision taken by the Italian Medicines Agency (AIFA) till September 2019.ResultsThe analysis allowed to define a taxonomy to distinguish categories of VF relevant to onco-hematological treatments. We identified the “real-world” VF that emerged given past P&R decisions taken at the Italian level. Data was collected both for clinical and economical outcomes/indicators, as well as decisions taken on innovativeness of therapies. Relevant differences emerge between the real world value framework and the one that should be applied given the normative framework of the Italian Health System.ConclusionsThe value framework that emerged from the analysis addressed issues of specific aspects of onco-hematological treatments which emerged during an ad hoc analysis conducted on treatment authorized in the last 5 years. The perspective adopted to elaborate the VF was the one of an HTA agency responsible for P&R decisions at a national level. Furthermore, comparing a real-world value framework with the one based on the general criteria defined by the national legislation, our analysis allowed identification of the most critical point of the current national P&R process in terms ofsustainability of current and future therapies as advance therapies and agnostic-tumor therapies.


2014 ◽  
Vol 120 ◽  
pp. 197-200 ◽  
Author(s):  
S.G. Altstadt ◽  
T. Adachi ◽  
Y. Aksyutina ◽  
J. Alcantara ◽  
H. Alvarez-Pol ◽  
...  

Author(s):  
Virginia Ronco ◽  
Myriam Dilecce ◽  
Elena Lanati ◽  
Pier Luigi Canonico ◽  
Claudio Jommi

Abstract Background Advanced therapy medicinal products (ATMPs) represent an important cornerstone for innovation in healthcare. However, uncertainty on the value, the high average cost per patient and their one-shot nature has raised a debate on their assessment and appraisal process for pricing and reimbursement (P&R) purposes. This debate led experts providing for recommendations on this topic. Our primary objective is to investigate the ATMPs P&R process in the main five European countries and to understand if this process is consistent with published P&R expert recommendations. We also investigated the current ATMP pipelines to understand if future ATMPs will create challenges for their P&R process. Methods P&R framework for ATMPs in the European Major five (EU5) countries was investigated through a literature search on PubMed, institutional websites of National Health Authorities and grey literature. The ATMPs pipeline database was populated from a clinical trial database (clinicaltrials.gov), relying on inclusion and exclusion criteria retrieved from the literature. Results Reimbursement status of ATMPs is different across the EU5 countries, with the exception of CAR-Ts which are reimbursed in all countries. Standard P&R process in place for other medicinal products is extended to ATMPs, with the exception of some cases in Germany. List prices, where available, are high and, tend to be aligned across countries. Outcome-based Managed Entry Agreements (MEAs) have been extensively used for ATMPs. Extra-funds for hospitals managing ATMPs were provided only in Germany and, as additional fund per episode, in France. The accreditation process of hospitals for ATMPs management was in most countries managed by the national authorities. As far as ATMPs pipeline is concerned, ATMPs in development are mostly targeting non-rare diseases. Conclusions Expert recommendations for ATMPs P&R were partially applied: the role of outcome-based MEAs has increased and the selection process of the centres authorized to use these treatments has been enhanced; additional funding for ATMPs management to accredited centres has not been completely considered and annuity payment and broader perspective in cost considerations are far from being put in place. These recommendations should be considered for future P&R negotiations to pursue rational resource allocation and deal with budget constraints.


Sign in / Sign up

Export Citation Format

Share Document